Clinical trial
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors &…
NCT00023166 · Enzon Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00023166 |
|---|---|
| Title | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas |
| Official title | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas |
| Lead sponsor | Enzon Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasm, Lymphomas, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | PEG-paclitaxel |
| Start date | May 1, 2001 |
| Completion | May 1, 2002 |
| First posted | Aug 27, 2001 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: